苏州昀冢电子科技股份有限公司2025 年第一季度报告 单位：元 币种：人民币 证券代码：688260 证券简称：昀冢科技 苏州昀冢电子科技股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 | 项目 | 本报告期 | 本报告期比上 上年同期 | | | --- | --- | --- | --- | | | | 年同期增减变 | | | | | 动幅度(%) | | | 营业收入 | 100,319,737.00 | 141,354,613.98 | -29.03 | | 归属于上市公司股东的净利润 | -52,216,961.76 ...

Financial Performance - The company's operating revenue for Q1 2025 reached ¥197,651,861.61, representing a 44.46% increase compared to ¥136,823,208.53 in the same period last year[5] - Net profit attributable to shareholders was ¥61,931,236.61, a significant increase of 164.23% from ¥23,438,331.42 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥50,842,098.63, up 59.73% from ¥31,829,980.34 in the previous year[6] - Basic and diluted earnings per share were both ¥0.46, reflecting a 170.59% increase compared to ¥0.17 in the same period last year[6] - The total comprehensive income for Q1 2025 was CNY 61.99 million, compared to CNY 23.23 million in Q1 2024, reflecting an increase of approximately 166.9%[19] Cash Flow and Investments - The net cash flow from operating activities was ¥22,077,510.27, a remarkable increase of 374.99% from a negative cash flow of -¥8,028,380.20 in the previous year[6] - Investment activities resulted in a net cash outflow of CNY 123.62 million in Q1 2025, compared to a net inflow of CNY 37.38 million in Q1 2024[24] - The company received CNY 255.72 million in cash from sales and services in Q1 2025, compared to CNY 126.48 million in Q1 2024, representing an increase of about 102.2%[23] Research and Development - Total R&D investment amounted to ¥51,313,554.34, which is a 47.51% increase from ¥34,785,458.24 year-on-year, accounting for 25.96% of operating revenue[6] - The company continues to focus on increasing R&D personnel and salaries, contributing to the growth in R&D investment[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,873,633,957.75, a 1.72% increase from ¥3,808,080,455.23 at the end of the previous year[6] - Current assets as of March 31, 2025, totaled RMB 2,990,721,220.61, slightly up from RMB 2,934,292,569.32 as of December 31, 2024[13] - Total liabilities as of March 31, 2025, were RMB 238,034,201.42, a slight increase from RMB 237,799,660.03[15] - Non-current assets totaled RMB 882,912,737.14, up from RMB 873,787,885.91, indicating a growth of 1.4%[14] Shareholder Information - Shareholders' equity attributable to the parent company was ¥3,635,599,756.33, up 1.83% from ¥3,570,280,795.20 at the end of the previous year[6] - Shareholders' equity increased to RMB 3,635,599,756.33 from RMB 3,570,280,795.20, reflecting a growth of 1.8%[15] - The company reported no significant changes in the top 10 shareholders or their participation in margin trading[11] Operational Status - There are no other important reminders regarding the company's operational status during the reporting period[12] - The company adjusted its financial statements for Q1 2024, increasing operating costs by CNY 1.75 million and decreasing sales expenses by the same amount due to new accounting standards[20]

Financial Performance - The company's revenue for Q1 2025 was CNY 137,160,578.06, representing a year-over-year increase of 20.02% compared to CNY 114,282,281.78 in the same period last year[4]. - The net loss attributable to shareholders for the period was CNY 11,545,431.51, a significant improvement from a loss of CNY 170,095,866.61 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥137,160,578.06, an increase of 20.00% compared to ¥114,282,281.78 in Q1 2024[18]. - Net profit for Q1 2025 was a loss of ¥11,545,431.51, an improvement from a loss of ¥174,882,984.28 in Q1 2024[19]. - The total comprehensive loss for Q1 2025 was ¥11,549,283.95, an improvement from a loss of ¥174,560,182.55 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities was a net outflow of CNY 13,801,882.53, which is an improvement of CNY 94,393,791.82 compared to the previous year's outflow[7]. - Cash flow from operating activities showed a net outflow of ¥13,801,882.53 in Q1 2025, compared to a net outflow of ¥108,195,674.35 in Q1 2024[21]. - Cash flow from investing activities resulted in a net outflow of ¥437,359,085.65 in Q1 2025, contrasting with a net inflow of ¥275,011,228.44 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,055,668,836.98, down from ¥2,374,907,374.57 at the end of Q1 2024[22]. Research and Development - Research and development (R&D) expenses totaled CNY 88,924,234.66, a decrease of 28.48% from CNY 124,328,450.39 in the same period last year, with R&D expenses accounting for 64.83% of revenue, down 43.96 percentage points[4][7]. - Research and development expenses were ¥72,712,590.56 in Q1 2025, down 25.00% from ¥96,745,611.33 in Q1 2024[18]. - The company continues to focus on enhancing R&D efficiency and integrating resources across different pipelines to drive future growth[7]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,820,387,409.65, a decrease of 1.73% from CNY 7,958,132,235.38 at the end of the previous year[5]. - The company's current assets totaled CNY 4,134,286,329.53, down from CNY 4,282,490,715.65, indicating a decrease of about 3.45%[13]. - The company's total liabilities were CNY 2,921,615,159.54, down from CNY 3,048,260,581.65, showing a reduction of around 4.17%[15]. - The total equity attributable to the owners of the parent company was CNY 4,898,772,250.11, slightly decreasing from CNY 4,909,871,653.73, a change of about 0.23%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,828[9]. - The company has not reported any significant changes in its major shareholders or their participation in margin trading activities[11]. Profitability Metrics - The weighted average return on equity improved by 3.04 percentage points to -0.24% from -3.28% in the previous year[4]. - The company's gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost control measures[7]. - The company's inventory increased to CNY 322,559,055.80 from CNY 283,414,610.09, marking an increase of approximately 13.80%[13]. - The company's short-term borrowings decreased to CNY 213,622,195.45 from CNY 377,348,417.32, a reduction of about 43.45%[15]. - The company's long-term borrowings increased to CNY 1,114,926,712.74 from CNY 1,098,538,320.81, reflecting an increase of approximately 1.49%[15].

Financial Performance - The company achieved a sales revenue of 360 million RMB, representing a year-on-year growth of 294.24% compared to 2023[3]. - The company's revenue for 2024 reached ¥359,900,621.06, representing a 294.24% increase compared to ¥91,288,640.00 in 2023[24]. - The net profit attributable to shareholders for 2024 was -¥845,956,285.93, an improvement from -¥1,107,713,253.26 in 2023[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was -¥898,889,978.56, compared to -¥1,160,727,128.66 in 2023[24]. - The net cash flow from operating activities for 2024 was -¥650,525,464.27, an improvement from -¥967,882,951.13 in 2023[24]. - The total assets as of the end of 2024 were ¥1,718,737,884.05, a 14.86% increase from ¥1,496,378,567.44 at the end of 2023[24]. - The net assets attributable to shareholders decreased by 77.17% to ¥193,755,800.40 at the end of 2024 from ¥848,627,415.80 at the end of 2023[24]. - The company reported a net profit attributable to shareholders of -224.23 million yuan in Q1 2024, with a total of -287.50 million yuan in Q4 2024[29]. - The net cash flow from operating activities was negative, totaling -126.07 million yuan in Q1 2024 and -187.22 million yuan in Q4 2024[29]. - The company reported a significant increase in production and sales volume of anti-tumor drugs, with sales volume rising by 302.3% year-on-year[101]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[163]. Research and Development - R&D expenses reached 724 million RMB during the reporting period, reflecting the company's ongoing investment in clinical trials[5]. - The company is focused on innovative drug research and development in the fields of malignant tumors and autoimmune diseases[3]. - The company has established a product pipeline with seven globally competitive products, including two in global registration clinical trials[38]. - The company invested CNY 724 million in R&D during the reporting period, with ongoing clinical trials for Shuwozhe® and DZD8586 progressing efficiently[42]. - The company has made significant progress in R&D, with a focus on addressing unmet needs in drug development, particularly in oncology[64]. - The company has established a comprehensive R&D platform covering all stages from drug discovery to clinical development, enhancing its core competitiveness in the pharmaceutical industry[76]. - The company has a total of 267 R&D personnel, accounting for 31.34% of the total workforce, with an average salary of 76.53 thousand RMB[75]. - The company has received 73 new intellectual property rights this year, bringing the total to 336[67]. - The company has developed new technologies and models to address drug resistance in targeted therapies, including next-generation TKIs and immune checkpoint inhibitors[64]. - The company is focusing on maintaining a strong R&D investment strategy to support the development of innovative therapies[125]. Product Development and Approvals - The self-developed Class I new drug, Gorizhe® (generic name: Golixitinib capsules), was approved for marketing in China, being the world's first and only highly selective JAK1 inhibitor for r/r PTCL[4]. - The commercialized products Shuwozhe® (generic name: Shuwotini tablets) and Gorizhe® were included in the National Medical Insurance Drug List for 2024[4]. - The FDA accepted the New Drug Application for Shuwozhe® and granted it priority review status for specific NSCLC patients[4]. - The company’s leading product, Gao Ruizhe®, received approval for market launch in June 2024, addressing a significant unmet clinical need in the treatment of r/r PTCL[38]. - Shuwozhe® has submitted a New Drug Application (NDA) to the FDA for the treatment of EGFR Exon20ins NSCLC, receiving priority review status based on positive results from the global clinical study "WU-KONG1B" and has been recognized as a breakthrough therapy in both China and the U.S.[40]. - Both Shuwozhe® and Gao Ruizhe® have been included in the national medical insurance drug list, effective January 1, 2025, which is expected to accelerate commercialization[41]. Market Strategy and Expansion - The company plans to expand its commercialization team and increase promotional efforts to capture a larger market share[5]. - The company is focused on expanding its market presence and developing new products and technologies[18]. - The company is actively communicating with overseas drug regulatory agencies to accelerate the overseas market entry of its products[54]. - The company aims to fill unmet clinical needs with innovative therapies in oncology and immune diseases, focusing on first-in-class drug development[38]. - The company is currently not profitable, primarily due to significant R&D investments and the early stage of commercialization, with a cumulative loss expected to increase[78]. - The company is exploring potential mergers and acquisitions to further enhance its market position, as indicated by the strategic share allocations for senior management[156]. Governance and Management - The company is committed to enhancing its governance structure by establishing specialized committees under the board, including a strategy committee and an audit committee[149]. - The board of directors consists of 7 members, including 4 independent directors, and has held 6 meetings during the reporting period, ensuring effective governance[149]. - The supervisory board comprises 3 members, with 2 employee supervisors, and has convened 5 meetings, fulfilling its supervisory responsibilities[150]. - The company has implemented a competitive compensation system and transparent promotion pathways to attract and retain talent[143]. - The company emphasizes a "shareholder-centric" development philosophy, aiming to improve internal management efficiency and enhance the quality of the listed company[146]. - The financial director has a strong background in investment banking and has held key positions in major financial institutions, which may improve the company's financial strategies[158]. Risks and Challenges - The company has outlined various risk factors in its annual report that may impact its operations[6]. - The approval process for new drugs is uncertain, and delays could adversely affect the company's business operations[84]. - The company is exposed to risks from market competition, particularly from larger multinational and domestic companies with more extensive commercialization experience[88]. - The company faces risks related to the quality control of drug production, which could significantly impact its market reputation and operational performance[87]. - The company relies on external financing for operational funding, and any shortfall could pressure its financial situation and delay R&D projects[90]. Employee and Training Initiatives - The workforce has grown to 852 employees, a 46.64% increase year-over-year, reflecting the company's commitment to talent development and enhancing core competitiveness[43]. - Over 350 employees participated in various training programs in 2024, achieving a satisfaction rate of 95%[185]. - More than 90% of middle and senior management have completed the "Excellence Management Advancement Program," enhancing management skills and team efficiency[184]. - The company has a comprehensive training system covering compliance, safety, and professional skills, ensuring 100% coverage of occupational health and safety training[184].

上海仁度生物科技股份有限公司2025 年第一季度报告 第一季度财务报表是否经审计 □是 √否 证券代码：688193 证券简称：仁度生物 上海仁度生物科技股份有限公司 2025 年第一季度报告 一、主要财务数据 (一)主要会计数据和财务指标 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 √适用 □不适用 上海仁度生物科技股份有限公司2025 年第一季度报告 单位:元 币种:人民币 上海仁度生物科技股份有限公司2025 年第一季度报告 单位：元 币种：人民币 | 非经常性损益项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动性资产处置损益，包括已计提资产减值准备的冲销部分 | | | | 计入当期损益的政府补助，但与公司正 ...

Financial Performance - The company reported an undistributed profit of RMB 107,872,303.37 as of December 31, 2024[7]. - The proposed cash dividend distribution is RMB 1.00 per 10 shares, totaling RMB 3,870,857.20 for 38,708,572 shares participating in the distribution[7]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2024 was CNY 177,351,527.35, representing a year-over-year increase of 7.87% compared to CNY 164,412,273.10 in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY -7,812,187.82, a significant decrease of 194.59% from CNY 8,259,296.58 in 2023[25]. - The basic earnings per share for 2024 was CNY -0.20, down 195.24% from CNY 0.21 in 2023[26]. - The cash flow from operating activities for 2024 increased by 41.85% to CNY 24,387,207.40, compared to CNY 17,191,765.24 in 2023[25]. - The company's total assets decreased by 5.72% to CNY 994,358,320.65 at the end of 2024, down from CNY 1,054,715,696.08 at the end of 2023[25]. - The company reported a net loss of CNY 19,559,897.22 after excluding non-recurring gains and losses, compared to a loss of CNY 10,298,455.81 in 2023[25]. - The company recorded non-recurring gains of CNY 11,747,709.40 in 2024, compared to CNY 18,557,752.39 in 2023[31]. Revenue and Growth - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a year-over-year growth of 25%[24]. - User data indicates that the number of active users has grown to 500,000, an increase of 40% compared to the previous year[24]. - The company has provided guidance for the next quarter, expecting revenue to be between RMB 1.3 billion and RMB 1.5 billion, which would imply a growth rate of 8% to 25%[24]. - A recent acquisition of a biotech firm is projected to add an additional RMB 300 million in annual revenue[24]. - The revenue from testing reagents was RMB 162.16 million, up 9.94% year-on-year, while instrument revenue reached RMB 8.71 million, growing by 19.88%[37]. Research and Development - The company is investing 10% of its revenue into R&D for new diagnostic technologies, aiming to launch three new products by the end of the fiscal year[24]. - Research and development expenses accounted for 22.08% of operating revenue in 2024, a decrease of 2.94 percentage points from 25.02% in 2023[26]. - The total R&D investment for the year was approximately ¥39.17 million, a decrease of 4.79% compared to the previous year, with R&D expenses accounting for 22.08% of operating income[85]. - The company applied for 5 new invention patents and obtained 8 new patents during the reporting period, enhancing its competitive edge[40]. - The company has developed a proprietary RNA real-time fluorescence isothermal amplification (SAT) technology platform, distinguishing itself from traditional DNA and protein-based diagnostic methods[70]. Product Development and Innovation - New product launches include a state-of-the-art nucleic acid detection system, which is expected to enhance testing efficiency by 30%[24]. - The company launched a new product, the Hepatitis C virus nucleic acid detection kit, which received regulatory approval in February 2024[38]. - The company has developed a nucleic acid detection kit for Mycobacterium tuberculosis, aiding in the diagnosis and treatment of tuberculosis[50]. - The company has introduced a hepatitis B virus nucleic acid detection kit, which is crucial for assessing treatment efficacy and predicting recurrence risks[50]. - The company launched the world's first HBV RNA detection product for hepatitis B precision diagnosis, enhancing its product line in blood source products[72]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share within the next two years[24]. - The company completed the registration of multiple products in international markets, including Turkey, and is expanding its presence in Southeast Asia and the Middle East[42]. - The company aims to expand its market presence through innovative product offerings and strategic partnerships in the healthcare sector[49]. - The company is exploring global market opportunities in molecular diagnostics and leveraging digital economy trends to develop home-based diagnostic solutions[77]. - The company is actively integrating its supply chain in the in vitro diagnostic industry, reducing reliance on external suppliers while enhancing production automation[76]. Operational Efficiency - The gross margin for the latest quarter improved to 60%, up from 55% in the previous quarter[24]. - The company achieved a testing throughput increase of 50%, allowing for more samples to be processed in the same timeframe[24]. - The company plans to enhance its distribution network, aiming for a 20% increase in operational efficiency by the end of the year[24]. - The AutoSAT system is the first domestic high-throughput, fully automated RNA nucleic acid detection analysis system, capable of processing up to 200 samples in 24 hours, significantly reducing reporting time compared to conventional PCR methods[53][54]. Governance and Compliance - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective checks and balances[157]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[157]. - The independent directors and supervisors have maintained their positions without any changes in shareholding during the reporting period[163]. - The company has not engaged in any significant competitive activities with its controlling shareholders that could adversely affect its operations[157]. - The company is committed to improving internal governance and compliance to mitigate operational risks and ensure sustainable development[152]. Risks and Challenges - The company faces potential risks related to pricing pressure and slower-than-expected revenue growth due to changes in market demand and macroeconomic conditions[104]. - The company is exposed to intensified market competition, particularly in the molecular diagnostics sector, with many new entrants[109]. - The company faces risks related to new product registration, which typically takes 3-5 years and requires significant investment[106]. - There is a risk of core technical personnel turnover, which could adversely affect ongoing projects and competitive advantage[106]. - The industry is under significant regulatory scrutiny, with new policies affecting procurement and pricing strategies for diagnostic products[110].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥159,641,464.34, representing a 96.32% increase compared to ¥81,318,560.00 in the same period last year[4] - The net loss attributable to shareholders was ¥192,513,348.95, an improvement from a loss of ¥224,234,890.87 year-over-year[4] - The total operating revenue for Q1 2025 was CNY 159,641,464.34, a significant increase from CNY 81,318,560.00 in Q1 2024, representing a growth of approximately 96%[19] - The net loss for Q1 2025 was CNY 193,740,729.91, an improvement from a net loss of CNY 224,234,890.87 in Q1 2024, reflecting a reduction in losses of approximately 14%[20] - The basic and diluted earnings per share for Q1 2025 were both CNY -0.46, compared to CNY -0.54 in Q1 2024, showing an improvement in earnings per share[21] Research and Development - Research and development expenses totaled ¥210,333,356.42, a slight increase of 2.72% from ¥204,770,425.91 in the previous year[5] - The ratio of R&D expenses to operating revenue decreased to 131.75%, down from 251.81% in the previous year, indicating a significant increase in revenue[5] - Research and development expenses for Q1 2025 were CNY 210,333,356.42, slightly up from CNY 204,770,425.91 in Q1 2024, showing a year-over-year increase of about 2%[20] - The new drug application for Shuwozhe® has been accepted by the FDA with priority review designation for specific lung cancer patients[12] - The company’s new molecule GW5282 has been approved to commence Phase I clinical trials in China[13] - DZD8586's latest clinical data has been selected for oral presentation at the 2025 ASCO conference, highlighting its significance in chronic lymphocytic leukemia treatment[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,804,839,457.76, reflecting a 5.01% increase from ¥1,718,737,884.05 at the end of the previous year[5] - Total current assets reached RMB 1.02 billion as of March 31, 2025, compared to RMB 998.97 million at the end of 2024[16] - The total non-current assets were CNY 784,132,605.39, up from CNY 719,765,080.27, reflecting an increase of approximately 9%[18] - Total liabilities increased to CNY 1,781,305,350.81 from CNY 1,518,680,986.42, representing a growth of about 17%[18] - The equity attributable to shareholders decreased by 90.47% to ¥18,460,390.68 from ¥193,755,800.40 at the end of the previous year[5] - The company's total equity decreased to CNY 23,534,106.95 from CNY 200,056,897.63, indicating a decline of about 88%[18] Cash Flow - The company reported a net cash flow from operating activities of -¥131,666,959.46, slightly worse than -¥126,071,888.78 in the previous year[4] - The company's cash flow from operating activities for Q1 2025 was CNY 164,190,860.93, compared to CNY 96,462,224.00 in Q1 2024, indicating a substantial increase in cash inflow[23] - Net cash flow from operating activities was -$131.67 million, compared to -$126.07 million in the previous period, indicating a slight increase in cash outflow[24] - Cash inflow from operating activities totaled $189.48 million, up from $125.11 million, indicating a growth of about 51.5%[24] - Total cash inflow from investment activities was $732.18 million, down from $1.03 billion in the previous period, reflecting a decrease of approximately 29%[24] - Cash outflow for investment activities totaled $860.83 million, compared to $1.09 billion previously, showing a reduction of about 21%[24] - Net cash flow from financing activities was $262.62 million, an increase from $207.57 million in the prior period, representing a growth of approximately 26.5%[25] Government Support - The company received government subsidies amounting to ¥23,396,000.00, which are closely related to its normal business operations[6] Inventory and Assets - The company’s inventory decreased to RMB 37.54 million as of March 31, 2025, down from RMB 44.11 million at the end of 2024[16] - The company’s long-term assets include fixed assets valued at RMB 19.74 million and intangible assets valued at RMB 421.38 million as of March 31, 2025[16] - The company’s cash and cash equivalents amounted to RMB 252.51 million as of March 31, 2025, slightly up from RMB 250.16 million at the end of 2024[16]

Financial Performance - The company's revenue for Q1 2025 was ¥90,439,557.91, a decrease of 41.02% compared to ¥153,326,988.59 in the same period last year[3] - The net profit attributable to shareholders was -¥5,247,402.73, representing a decline of 169.22% from a profit of ¥7,581,160.86 in the previous year[3] - The basic earnings per share were -¥0.0617, down 168.60% from ¥0.0900 in the same period last year[3] - Net profit for Q1 2025 was a loss of ¥6,101,532.98, compared to a profit of ¥6,244,943.55 in Q1 2024, representing a significant decline[17] - The company reported a gross loss of ¥6,299,830.81 in Q1 2025, contrasting with a gross profit of ¥3,663,811.30 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities increased by 102.84% to ¥98,697,073.78, up from ¥48,657,809.26 year-on-year[3] - Cash inflows from operating activities in Q1 2025 totaled ¥270,982,750.63, slightly up from ¥269,162,596.56 in Q1 2024[21] - The total cash and cash equivalents at the end of the period reached $234,578,068.65, significantly higher than $96,114,372.78 at the end of the previous period[22] - The company reported a total cash outflow from operating activities of $172,285,676.85, down from $220,504,787.30, reflecting improved operational efficiency[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,232,636,747.40, reflecting a 7.56% increase from ¥2,075,682,593.71 at the end of the previous year[4] - Current assets totaled RMB 1,197,838,424.84, up from RMB 1,125,827,990.59, indicating an increase of about 6.4%[12] - The total liabilities increased to RMB 1,166,898,408.05 from RMB 1,003,842,721.38, representing a growth of approximately 16.3%[13] - The company’s equity remained stable at RMB 85,134,666.00, unchanged from the previous period[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,741[8] - The company’s major shareholder, Wands Investment, holds 28.88% of the shares, and a share transfer agreement has been signed with Ruiyuan International, which will result in a change of control[10] - The total equity attributable to shareholders of the parent company was ¥1,027,651,420.90, a slight decrease from ¥1,032,898,823.63[14] Operational Efficiency - The company faced a significant decline in revenue due to market environment factors and a focus on customer creditworthiness, leading to stricter customer selection standards[6] - The company incurred financial expenses of ¥4,169,995.96 in Q1 2025, an increase from ¥2,441,893.83 in Q1 2024[17] - The company experienced a significant increase in credit impairment losses, totaling ¥5,148,698.84 in Q1 2025, compared to ¥9,022,963.28 in Q1 2024[17] Investment Activities - Cash inflow from investment activities totaled $233,454,772.78, compared to $105,914,500.16 in the prior period, indicating a strong increase in investment returns[22] - The cash paid for investments was $223,000,000.00, compared to $68,104,069.44 in the previous period, indicating a strategic increase in capital expenditures[22] Research and Development - Research and development expenses totaled ¥4,806,981.53, a decrease of 24.98% from ¥6,407,936.09, while the R&D expense as a percentage of revenue increased to 5.32% from 4.18%[4] Accounting Standards - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[23]

Financial Performance - The company's operating revenue for Q1 2025 was ¥35,922,054.32, a decrease of 18.62% compared to ¥44,139,392.99 in the same period last year[3] - The net profit attributable to shareholders was -¥13,680,901.21, worsening from -¥7,273,734.39 year-on-year[3] - The net cash flow from operating activities was -¥29,964,460.23, compared to -¥19,583,685.98 in the previous year[3] - The basic and diluted earnings per share were both -¥0.17, compared to -¥0.09 in the same period last year[3] - Net profit for Q1 2025 was a loss of ¥13,728,189.49, compared to a loss of ¥7,273,734.39 in Q1 2024, indicating a worsening of 88.5%[18] - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by ¥6,407,200 compared to the previous year[8] - The total profit for Q1 2025 was -12,033,963.81 RMB, compared to -11,108,081.89 RMB in Q1 2024, indicating a further loss[30] Research and Development - Research and development expenses totaled ¥21,597,292.84, a slight decrease of 3.34% from ¥22,343,727.74 year-on-year[3] - R&D expenses accounted for 60.12% of operating revenue, an increase of 9.50 percentage points compared to 50.62% in the previous year[4] - Research and development expenses for Q1 2025 were ¥21,597,292.84, slightly down from ¥22,343,727.74 in Q1 2024[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,610[10] - The largest shareholder, Yang Tao, holds 18,625,000 shares, representing 23.65% of total shares[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three holding over 39%[10] Assets and Liabilities - The total current assets amount to 1,186,447,429.53 RMB, a decrease from 1,254,809,122.25 RMB in the previous period[13] - Total liabilities decreased from ¥174,260,365.07 in the previous period to ¥152,078,420.54 in the current period, a reduction of 12.7%[15] - Non-current assets increased to ¥203,280,184.37 from ¥163,061,924.85, reflecting a growth of 24.7%[14] - Total equity decreased from ¥1,243,610,682.03 to ¥1,237,649,193.36, a decline of 0.5%[15] - The total equity of the company was CNY 1,254,675,627.10, slightly down from CNY 1,256,728,291.64[27] Cash Flow - Cash received from sales of goods and services in Q1 2025 was ¥44,046,982.22, a decrease of 32.8% from ¥65,698,492.25 in Q1 2024[21] - Operating cash flow for Q1 2025 was -25,179,745.38 RMB, worsening from -18,779,701.93 RMB year-over-year[33] - The cash outflow for operating activities in Q1 2025 was 71,253,969.92 RMB, down from 85,991,125.90 RMB in Q1 2024, showing a reduction of 17.2%[33] - The company reported a net cash inflow from investment activities of CNY 108,728,931.56, an increase from CNY 65,172,502.65 in the previous period[22] Financial Stability - The company has no significant changes in the number of shares lent or borrowed through margin trading[12] - The company has not reported any new strategies or significant changes in operational status during the reporting period[12] - The company incurred a credit impairment loss of 530,940.08 RMB in Q1 2025, a significant increase from a gain of -89,688.07 RMB in Q1 2024[30]

Financial Performance - Operating revenue for Q1 2025 was CNY 6,700,423,651.41, an increase of 2.93% compared to CNY 6,509,426,910.25 in the same period last year[3] - Net profit attributable to shareholders decreased by 7.08% to CNY 561,678,908.50 from CNY 604,490,948.26 year-on-year[3] - Basic earnings per share decreased by 16.67% to CNY 0.05 from CNY 0.06 year-on-year[3] - Net profit for the first quarter of 2025 was CNY 652,303,752.78, a decrease of 8.5% compared to CNY 712,787,783.12 in the same period of 2024[18] - Total revenue from operating activities decreased to CNY 5,682,221,382.97 in Q1 2025, down 57.0% from CNY 13,219,785,766.72 in Q1 2024[20] - Operating revenue for Q1 2025 was CNY 372,968,089.76, a decrease of 50.16% compared to CNY 747,305,803.48 in Q1 2024[26] - Net profit for Q1 2025 was CNY 10,145,920.39, down 90.39% from CNY 105,754,373.03 in Q1 2024[27] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -3,996,015,804.00, compared to a positive CNY 2,082,321,318.72 in the previous year, indicating a significant change[3] - Operating cash flow turned negative at CNY -3,996,015,804.00 in Q1 2025, compared to a positive CNY 2,082,321,318.72 in Q1 2024[20] - The company’s cash flow from operating activities reflects a significant decrease, indicating potential challenges in revenue generation[29] - The net cash flow from operating activities was -241,921,943.84, compared to 201,714,792.86 in the previous period, indicating a significant decline[30] - Total cash inflow from investing activities was 276,334,282.36, while cash outflow was 463,918,261.96, resulting in a net cash flow of -187,583,979.60[30] - Cash inflow from financing activities was 2,000,000,000.00, with cash outflow totaling 2,014,296,944.44, leading to a net cash flow of -14,296,944.44[30] - The ending balance of cash and cash equivalents was 4,858,923,804.42, down from 5,302,768,166.35 at the beginning of the period[30] - The company reported a significant decrease in cash flow from operating activities, with total cash outflow reaching 712,612,824.37[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 116,066,949,868.92, a decrease of 1.55% from CNY 117,890,875,515.13 at the end of the previous year[4] - The total assets as of March 31, 2025, were CNY 116,066,949,868.92, compared to CNY 117,890,875,515.13 at the end of 2024[15] - The total liabilities decreased to CNY 64,943,804,942.65 from CNY 67,455,073,189.37 in the previous period[16] - Total assets amounted to CNY 43,490,383,882.03, slightly down from CNY 43,749,841,293.21 in the previous period[24] - Total liabilities decreased to CNY 9,241,810,729.21 from CNY 9,509,774,528.02[24] Research and Development - Research and development expenses totaled CNY 397,499,991.85, representing an increase of 5.64% from CNY 376,270,501.83 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 5.93% from 5.78% year-on-year[4] - Research and development expenses were CNY 379,609,678.30 in Q1 2025, slightly up from CNY 376,270,501.83 in Q1 2024[18] - Research and development expenses increased to CNY 3,030,387.35 in Q1 2025, compared to CNY 1,800.00 in Q1 2024[26] Shareholder Information - The company reported a total of 64,624 common shareholders at the end of the reporting period[8] - The largest shareholder, China Railway Communication Signal Group Co., Ltd., holds 62.46% of the shares, totaling 6,614,216,000 shares[8] Contracts and Revenue Sources - The total new external contracts signed in Q1 2025 amounted to CNY 72.13 billion, a decrease of 36.51% year-over-year[11] - The railway sector saw new contracts worth CNY 42.34 billion, a growth of 6.25% compared to the previous year[11] - The urban rail transit sector experienced a significant increase in new contracts, totaling CNY 22.42 billion, which is a 47.17% rise year-over-year[11] - The overseas business contracts decreased to CNY 3.43 billion, down 74.16% from the previous year[11]